相关实验视频
Updated: Jan 18, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
11.9K
诊断症状,治疗模式和医疗资源利用在多系统缩在美国
Sigal Kaplan1, Handing Xie2, Amit Kumar3
1Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Neurodegenerative disease management
|September 8, 2025
概括
多重系统缩 (MSA) 显著增加了各种症状的风险,如正静性低血压和记忆障碍. 这种神经退行性疾病还导致更高的药物使用和医疗保健资源利用率 (HCRU).
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
- 临床研究 临床研究
背景情况:
- 多种系统缩 (MSA) 是一种渐进的神经退行性疾病,其特征是多样化,经常复杂的症状.
- 准确的诊断和对MSA全临床谱的理解是具有挑战性的.
研究的目的:
- 描述与MSA相关的症状的范围.
- 分析MSA患者的药物使用情况.
- 评估与MSA相关的医疗保健资源利用率 (HCRU).
主要方法:
- 使用美国大型索赔数据库进行了一项回顾性队列研究.
- 2017-2021年新诊断的MSA患者 (≥30岁,≥2次诊断) 与对照组进行了匹配.
- 包括症状,处方和HCRU在内的结果在诊断后的第一年使用条件后勤回归进行了比较.
主要成果:
- 与对照组 (n=4748) 相比,MSA患者 (n=1187) 的许多症状发生率显著更高.
- 关键症状包括静止性低血压 (89.6x),记忆障碍 (9.2x),运动症状 (7.5x),跌倒 (6.4x),疲劳 (5.8x),情绪障碍 (5.5x) 和尿路功能障碍 (4.9x).
- 此外,MSA患者的药物使用量增加,HCRU增加,包括住院治疗.
结论:
- 这项现实研究强调了MSA的大量疾病负担.
- 这些发现强调了MSA对患者症状,治疗需求和医疗利用的广泛影响.
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Methods of Documentation VI: Case Management Model
864
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
864
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
475
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
475
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K

